|
rs2251219
|
|
Mood Disorders
|
|
0.810 |
GeneticVariation
|
GWASCAT |
We identified SNPs at 3p21.1 associated with major mood disorders (rs2251219, P = 3.63 x 10(-8); odds ratio = 0.87; 95% confidence interval, 0.83-0.92), with supportive evidence for association observed in two out of three independent replication cohorts.
|
20081856 |
2010 |
|
rs2251219
|
|
Mood Disorders
|
|
0.810 |
GeneticVariation
|
GWASDB |
We identified SNPs at 3p21.1 associated with major mood disorders (rs2251219, P = 3.63 x 10(-8); odds ratio = 0.87; 95% confidence interval, 0.83-0.92), with supportive evidence for association observed in two out of three independent replication cohorts.
|
20081856 |
2010 |
|
rs80278479
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs80164876
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs78087832
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs77945277
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs75995702
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs75507262
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs74860738
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs73788091
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs73720034
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs73425402
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs6546604
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs6063349
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs57043326
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs56388524
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs4839421
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs35863382
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs34807503
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs34177316
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs34102224
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs2402960
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs201921722
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs201569130
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
rs201203751
|
|
Mood Disorders
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |